Market Overview

Morgan Stanley Sees Growth Platforms Building for Stericycle

Related SRCL
Look For A 'Slow Bleed' Lower For Stericycle Shares Despite Q1 Beat
Benzinga's Top Upgrades, Downgrades For May 5, 2017

In a report published Thursday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Stericycle (NASDAQ: SRCL).

In the report, Morgan Stanley noted, “Organic revenue growth in 4Q13 ticked up slightly versus 3Q13 but remains consistent with 2012-13 trends. Greater traction from StrongPak is a modest positive but drove margin dilution. Full valuation and limited visibility on sustainable growth acceleration keeps us from a more constructive view.”

Stericycle closed on Wednesday at $116.48.

Latest Ratings for SRCL

May 2017BairdDowngradesNeutralUnderperform
Apr 2017BarclaysInitiates Coverage OnOverweight
Mar 2017Goldman SachsUpgradesSellNeutral

View More Analyst Ratings for SRCL
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings


Related Articles (SRCL)

View Comments and Join the Discussion!